552330-34-4

Upstream product

• 74115-13-2 5-bromopyridine-3-ol 
• 100-39-0 benzyl bromide 
• 100-51-6 benzyl alcohol 
• 625-92-3 3,5-dibromopyridine 
• 130722-95-1 3-(benzyloxy)-5-bromopyridine 

Downstream Products

• 1186637-46-6 5-(benzyloxy)-3-bromo picolinonitrile 
• 1393534-88-7 3-(benzyloxy)-5-bromopicolinonitrile 
• 1186635-29-9 2-(benzyloxy)benzo[f][1,7]naphthyridin-5-amine 
• 1314026-58-8 4-[6-cyano-5-(2-ethoxy-2-oxoethoxy)pyridin-3-yl]benzoic acid 
• 1314026-57-7 3-[6-cyano-5-(2-ethoxy-2-oxoethoxy)pyridin-3-yl]benzoic acid 
• 1314026-56-6 4-[6-chloro-5-(2-ethoxy-2-oxoethoxy)pyridin-3-yl]benzoic acid 
• 1314026-55-5 3-[6-chloro-5-(2-ethoxy-2-oxoethoxy)pyridin-3-yl]benzoic acid 
• 1314026-76-0 3-amino-6-(4-{[(4-biphenyl)amino]carbonyl}phenyl)-N-methylfuro[3,2-b]pyridine-2-carboxamide 
• 1314026-75-9 3-amino-6-(4-{[(3-biphenyl)amino]carbonyl}phenyl)-N-methylfuro[3,2-b]pyridine-2-carboxamide 
• 1314026-74-8 3-amino-6-(4-{[(3-chlorophenyl)amino]carbonyl}phenyl)-N-methylfuro[3,2-b]pyridine-2-carboxamide 
• 1314026-73-7 3-amino-6-(3-{[(4-biphenyl)amino]carbonyl}phenyl)-N-methylfuro[3,2-b]pyridine-2-carboxamide 
• 1314026-72-6 3-amino-6-(3-{[(4-fluorophenyl)amino]carbonyl}phenyl)-N-methylfuro[3,2-b]pyridine-2-carboxamide 
• 1314026-71-5 3-amino-6-(3-{[(4-chlorophenyl)amino]carbonyl}phenyl)-N-methylfuro[3,2-b]pyridine-2-carboxamide 
• 1314026-70-4 3-amino-6-(3-{[(3-biphenyl)amino]carbonyl}phenyl)-N-methylfuro[3,2-b]pyridine-2-carboxamide 

Relevant academic research and scientific papers

Homogenous suspension of immunopotentiating compounds and uses thereof

The present invention generally relates to homogeneous suspensions of small molecule immune potentiators (SMIPs) that are capable of stimulating or modulating an immune response in a subject in need thereof. The homogeneous suspensions may be used in combinations with various antigens or adjuvants for vaccine therapies.

A convenient route to functionalized 3-amino-N-methylfuro[3,2-b]pyridine-2- carboxamides

The synthesis of novel functionalized 3-amino-N-methylfuro[3,2-b]pyridine- 2-carboxamides is described from cyanopyridine intermediates. Based on the difference in halogen reactivity, ethyl [(5-bromo-2-chloropyridin-3-yl)oxy] acetate was functionalized by a palladium-catalyzed reaction, before the cyclization to the desired furo[3,2-b]pyridines.

COMPOUNDS AND COMPOSITIONS AS TLR ACTIVITY MODULATORS

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with Toll-Like Receptors, including TLR7 and TLR8. In one aspect, the compounds are useful as adjuvants for enhancing the effectiveness of a vaccine (formula I) wherein: X3 is N; X4 is N Or CR3; X5 is -CR4=CR5.

Isoquinoline-pyridine-based protein kinase B/Akt antagonists: SAR and in vivo antitumor activity

The structure-activity relationships of a series of isoquinoline-pyridine-based protein kinase B/Akt antagonists have been investigated in an effort to improve the major short-comings of the lead compound 3, including poor pharmacokinetic profiles in several species (e.g., mouse iv t1/2 = 0.3 h, po F = 0%). Chlorination at C-1 position of the isoquinoline improved its pharmacokinetic property in mice (iv t1/2 = 5.0 h, po F = 51%) but resulted in >500-fold drop in potency. In a mouse MiaPaCa-2 xenograft model, an amino analog 10y significantly slowed the tumor growth, however was accompanied by toxicity.